Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
High-quality meta-analysis of 8 RCTs with 7434 patients and 37.9-month follow-up reporting hard clinical endpoints (stroke, major bleeding) with precise effect estimates and confidence intervals, demonstrating no superiority of LAAC over OAC and a higher ischemic stroke risk.
A narrative review synthesizing evidence on GLP-1 and GIP/GLP-1 therapies across cardiovascular disease, diabetes, obesity, and heart failure—providing expert synthesis rather than new primary data.